Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | THPO | P40225 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.46 |
| ▸ | TNKS | O95271 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene SCHEMBL3240169 | 0.96 | CYP11B2 (0.61) | CYP11B2MEN1KMT2AKDM4ECYP3A4 | |
| Acetic Acid SCHEMBL27994757 | 0.91 | CYP11B2 (0.54) | CYP11B2MEN1KMT2AKDM4ECYP3A4 | |
| SCHEMBL24924079 | 0.89 | CYP11B2 (0.56) | CYP11B2MEN1KMT2AKDM4ECYP3A4 | |
| SCHEMBL990213 | 0.84 | — | — | |
| SCHEMBL29848157 | 0.84 | — | — | |
| Formaldehyde SCHEMBL28570916 | 0.82 | CYP11B2 (0.71) | CYP11B2MEN1KMT2AKDM4ECYP3A4 | |
| Ammonia Solution, Strong SCHEMBL28985148 | 0.82 | CYP11B2 (0.77) | CYP11B2MEN1KMT2ACHRNB2CHRNA4 | |
| Ethylene SCHEMBL1721957 | 0.81 | CYP11B2 (0.44) | CYP11B2MEN1KMT2AKDM4ECYP3A4 | |
| SCHEMBL26422507 | 0.81 | CYP11B2 (0.58) | CYP11B2MEN1KMT2AKDM4ECYP3A4 | |
| SCHEMBL30434052 | 0.80 | CYP11B2 (0.88) | CYP11B2MEN1KMT2ACHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4845228-A | INTERMEDIATES FOR CARDIOTONIC AGENTS | MITSUI TOATSU CHEMICALS, INC. (JP) | 1989-07-04 | — | — | US | claimed |
| EP-4638442-A1 | TRANSIENT RECEPTOR POTENTIAL VANILLOID 6 INHIBITORS | Uniquest Pty Limited (AU) | 2025-10-29 | — | — | EP | disclosed |
| WO-2024130342-A1 | TRANSIENT RECEPTOR POTENTIAL VANILLOID 6 INHIBITORS | UNIQUEST PTY LIMITED (AU) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024130342-A1 | TRANSIENT RECEPTOR POTENTIAL VANILLOID 6 INHIBITORS | UNIQUEST PTY LIMITED (AU) | 2024-06-27 | — | — | WO | disclosed |
| WO-2023014908-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | Pipeline Therapeutics, Inc. (US) | 2023-02-09 | — | — | WO | disclosed |
| CN-111712490-A | Amino-substituted pyridone derivatives, preparation method and medical application thereof | 上海海雁医药科技有限公司 | 2020-09-25 | — | — | CN | disclosed |
| EP-2582692-B1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-22 | — | — | EP | disclosed |
| US-9062048-B2 | Cyclohexyl-azetidinyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-23 | — | — | US | disclosed |
| US-8729063-B2 | 3-aminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2014-05-20 | — | — | US | disclosed |
| US-8637576-B2 | Benzamide derivatives and uses related thereto | AMGEN INC. (US) | 2014-01-28 | — | — | US | disclosed |
| EP-1904435-A2 | BENZAMIDE DERIVATIVES AND USES RELATED THERETO | Amgen Inc. (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007088401-A1 | INDAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LIMITED (GB) | 2007-08-09 | — | — | WO | disclosed |
| EP-1565436-A4 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORP (US) | 2007-07-18 | — | — | EP | disclosed |
| US-20060293392-A1 | Benzamide derivatives and uses related thereto | AMGEN INC. | 2006-12-28 | — | — | US | disclosed |
| WO-2006138508-A2 | BENZAMIDE DERIVATIVES AND USES RELATED THERETO | AMGEN INC. (US) | 2006-12-28 | — | — | WO | disclosed |
| US-20060252751-A1 | 3-Aminopyrrolidine derivaties as modulators of chemokine receptors | INCYTE HOLDINGS CORPORATION | 2006-11-09 | — | — | US | disclosed |
| EP-1565436-A2 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004050024-A2 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2004-06-17 | — | — | WO | disclosed |
| US-4845228-A | INTERMEDIATES FOR CARDIOTONIC AGENTS | MITSUI TOATSU CHEMICALS, INC. (JP) | 1989-07-04 | — | — | US | disclosed |
| US-4824952-A | CARDIOTONIC AGENTS | MITSUI TOATSU CHEMICALS, INC. (JP) | 1989-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252751-A1 | 3-Aminopyrrolidine derivaties as modulators of chemokine receptors | CCR2, CXCR3, CCR5 | CYP11B2 2496/4885MEN1 4347/4885KMT2A 3605/4885 |
| US-20060293392-A1 | Benzamide derivatives and uses related thereto | GPR119, GLP1R, UGT2B7 | CYP11B2 310/4885MEN1 2543/4885KMT2A 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.